CN111265665A - Pharmaceutical composition for treating cervical cancer and pharmaceutical application thereof - Google Patents
Pharmaceutical composition for treating cervical cancer and pharmaceutical application thereof Download PDFInfo
- Publication number
- CN111265665A CN111265665A CN202010194278.2A CN202010194278A CN111265665A CN 111265665 A CN111265665 A CN 111265665A CN 202010194278 A CN202010194278 A CN 202010194278A CN 111265665 A CN111265665 A CN 111265665A
- Authority
- CN
- China
- Prior art keywords
- cervical cancer
- pharmaceutical composition
- licochalcone
- pharmaceutical
- apatinib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010008342 Cervix carcinoma Diseases 0.000 title claims abstract description 43
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 title claims abstract description 43
- 201000010881 cervical cancer Diseases 0.000 title claims abstract description 43
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 33
- DRDRYGIIYOPBBZ-XBXARRHUSA-N Licochalcone B Natural products COC1=C(O)C(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1 DRDRYGIIYOPBBZ-XBXARRHUSA-N 0.000 claims abstract description 60
- 229940124674 VEGF-R inhibitor Drugs 0.000 claims abstract description 22
- 230000000694 effects Effects 0.000 claims abstract description 22
- 229960003982 apatinib Drugs 0.000 claims abstract description 21
- WPEWQEMJFLWMLV-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 WPEWQEMJFLWMLV-UHFFFAOYSA-N 0.000 claims abstract description 21
- WBDNTJSRHDSPSR-UHFFFAOYSA-N Licochalcone C Natural products C1=CC(O)=C(CC=C(C)C)C(OC)=C1C=CC(=O)C1=CC=C(O)C=C1 WBDNTJSRHDSPSR-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229930187586 licochalcone Natural products 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims abstract description 10
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 15
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 6
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 6
- 229960002411 imatinib Drugs 0.000 claims description 6
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 6
- 229960004891 lapatinib Drugs 0.000 claims description 6
- 208000034254 Squamous cell carcinoma of the cervix uteri Diseases 0.000 claims description 3
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 9
- 230000001093 anti-cancer Effects 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 206010028980 Neoplasm Diseases 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 16
- 241000700159 Rattus Species 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 241000701806 Human papillomavirus Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003527 anti-angiogenesis Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 208000019065 cervical carcinoma Diseases 0.000 description 3
- 235000005513 chalcones Nutrition 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- -1 chalcone compound Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 1
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 206010057175 Mass conditions Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 229940091171 VEGFR-2 tyrosine kinase inhibitor Drugs 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000011122 anti-angiogenic therapy Methods 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000009803 radical hysterectomy Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
The invention relates to the technical field of medicines, in particular to a pharmaceutical composition for treating cervical cancer and pharmaceutical application thereof. The pharmaceutical composition of the invention comprises effective dose of licochalcone and VEGFR inhibitor, has synergistic inhibition effect on HeLa S3 cervical cancer cell strain, and has more obvious anticancer effect when the two are combined compared with the single use of one of the active ingredients. In particular, when licochalcone B and apatinib are mixed in a molar ratio of 1:3, the inhibition effect is optimal when the components are mixed, and the treatment effect of the medicine can be obviously improved.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a pharmaceutical composition for treating cervical cancer and pharmaceutical application thereof.
Background
Cervical cancer is one of the malignant tumors that seriously threaten the health of women worldwide. In a global cancer survey of 2018, the incidence and mortality of cervical cancer is located at the 4 th position of all female malignancies. An estimated 53 million new cases per year with 27 million deaths. In China, about 13 thousands of new cases of cervical cancer occur each year, about 5.3 thousands of cases die, and the number of deaths accounts for about 18.4% of deaths of female patients caused by malignant tumors.
The development of cervical cancer is a complex and slow process, and the cervical cancer develops from cervical epitheliosis intratumoral transformation to invasive cervical cancer, and the specific pathogenesis is not clear. It is currently believed that cervical cancer occurs in association with Human Papillomavirus (HPV), that more than 90% of cervical cancer patients have HPV infections, and that almost all cervical cancers are associated with HPV, including cervical squamous cell carcinoma (70%), cervical adenocarcinoma (25%) and mixed histological tumors. HPV is a group of small non-enveloped double-stranded DNA viruses belonging to the papovaviridae family, which are similar to polyomaviruses and consist of about 72 chitosans; the genome of HPV is a circular structure comprising DNA of 7500-8000bp related to histones, compressed into chromatin-like aggregates.
At present, the treatment modes of cervical cancer mainly adopt surgical treatment, external radiation radiotherapy, intracavity radiotherapy and auxiliary chemotherapy. The early cervical cancer is usually treated by an operation, and the operation mode is radical hysterectomy plus pelvic lymph node cleaning, so that the treatment effect is good; radiation therapy can be used when not indicated by surgery, and cervical cancer is generally sensitive to radiation therapy, but has a relatively poor prognosis for advanced and recurrent cervical cancer. Despite advances in surgical and adjuvant therapies, development and recurrence of the disease continues to afflict women with cervical cancer, and finding effective treatments is critical, especially in middle-to-advanced and recurrent patients, where effective chemotherapy is important. Anti-angiogenesis (bevacizumab) targeted therapy has improved the quality of life of patients with recurrent metastatic cervical cancer, while the use of other new molecularly targeted drugs and immune checkpoint inhibitors is actively explored.
Disclosure of Invention
The invention aims to solve the technical problem of the prior art and provides a pharmaceutical composition for treating cervical cancer and pharmaceutical application thereof. The invention combines licochalcone and VEGFR inhibitor to treat cervical cancer, greatly improves the use effect of single medicine. Experiments prove that the licochalcone and VEGFR inhibitor combined drug can obviously inhibit the proliferation of cervical cancer cells.
In order to solve the technical problems, the invention adopts the technical scheme that:
a pharmaceutical composition for treating cervical cancer comprises licochalcone and VEGFR inhibitor with effective dose.
Preferably, the molar ratio of the licochalcone to the VEGFR inhibitor is (1-5) to (5-10).
Preferably, the molar ratio of licochalcone to VEGFR inhibitor is 1: 3.
Preferably, the licochalcone is licochalcone B.
Preferably, the VEGFR inhibitor is selected from one or more of apatinib, imatinib, lapatinib.
Preferably, the VEGFR inhibitor is selected from apatinib.
Preferably, the cervical cancer is cervical squamous cell carcinoma.
Furthermore, the invention also provides a pharmaceutical preparation with the effect of treating cervical cancer, which comprises the pharmaceutical composition and pharmaceutic conventional auxiliary materials.
Preferably, the preparation is selected from one or more of tablets, capsules, granules and injections.
Further, the invention also provides application of the pharmaceutical composition in preparing a medicine for treating cervical cancer.
The chalcone compound molecules can be combined with different biological receptors, and have obvious inhibition effect on tumor cell proliferation, and the action mechanism comprises the following components: inhibition of tubulin polymerization, anti-angiogenesis, induction of apoptosis, anti-estrogen and reversal of multidrug resistance. Research shows that chalcone is an important compound type of a novel antitumor drug or an antitumor auxiliary drug with application prospect. Licochalcone is a newly discovered estrogen flavone, which can be divided into several different types. Licochalcone B (lico B) is a chalcone compound obtained from Glycyrrhiza plants, exists in root and stem of Glycyrrhiza uralensis Fisch of Leguminosae, is yellow needle crystal, and is difficult to dissolve in water. Research reports that Lico B has the effects of resisting inflammation, resisting bacteria (having strong inhibitory activity on gram-positive bacteria), resisting oxidation, resisting Alzheimer disease, protecting liver and the like. Recent studies have reported that Lico B also has significant antitumor activity, which can inhibit the proliferation of tumor cells and induce cell cycle arrest and apoptosis of tumor cells.
Angiogenesis abnormalities are a key factor in the development of a variety of diseases, including tumors, and the process is complex and involves highly regulated interactions of multiple signaling molecules. The angiogenesis promoting signal molecules such as VEGF, VEGFR-2 and the like are highly expressed in various human tumors and play an important role in tumor neovascularization. Because of its important role in tumor development, the vascular system has become one of the targets for tumor therapy. The anti-angiogenesis therapy can normalize the tumor vasculature by preventing the expansion of the tumor vasculature, thereby improving the blood circulation conditions around the tumor, enabling the cytotoxic drug to be uniformly delivered to the tumor tissue core, and enhancing the anti-tumor effect of the drug. In addition, anti-angiogenic therapies can also reduce the chemotherapy resistance of tumor cells by improving hypoxic microenvironment and reducing interstitial pressure. The above studies suggest that targeting multiple molecules in the angiogenic cascade with an angiogenesis inhibitor optimizes inhibition of angiogenesis and may improve clinical therapeutic efficacy in cervical cancer patients. Apatinib is a novel micromolecular VEGFR-2 tyrosine kinase inhibitor independently developed in China, and the main action mechanism of the Apatinib is that the VEGFR-2 tyrosine kinase activity is inhibited, the signal transduction of the combined VEGF and the receptor thereof is blocked, and the tumor angiogenesis is inhibited.
Compared with the prior art, the invention has the beneficial effects that: the inventor unexpectedly finds that the licochalcone and the VEGFR inhibitor have synergistic inhibition effect on a HeLa S3 cell line when being simultaneously administered, and the anticancer effect is more obvious when the licochalcone and the VEGFR inhibitor are used together compared with the anticancer effect when one of the active ingredients is singly used. In particular, when licochalcone B and apatinib are mixed in a molar ratio of 1:3, the inhibition effect is optimal when the components are mixed, and the treatment effect of the medicine can be obviously improved.
Detailed Description
The technical solutions in the embodiments of the present invention are clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention. The materials, reagents and the like used are, unless otherwise specified, commercially available reagents and materials.
Example 1
A pharmaceutical composition for treating cervical cancer comprises an effective amount of licochalcone B and apatinib, wherein the molar ratio of the licochalcone B to the apatinib is 1: 3.
Example 2
A pharmaceutical composition for treating cervical cancer comprises effective amounts of licochalcone B and imatinib, wherein the molar ratio of licochalcone B to imatinib is 1: 3.
Example 3
A pharmaceutical composition for treating cervical cancer comprises effective amounts of licochalcone B and lapatinib, wherein the molar ratio of licochalcone B to lapatinib is 1: 3.
Example 4
A pharmaceutical composition for treating cervical cancer comprises an effective amount of licochalcone B and apatinib, wherein the molar ratio of the licochalcone B to the apatinib is 1: 10.
Example 5
A pharmaceutical composition for treating cervical cancer comprises an effective amount of licochalcone B and apatinib, wherein the molar ratio of the licochalcone B to the apatinib is 1: 1.
Comparative example 1
A pharmaceutical composition for treating cervical cancer comprises licochalcone B with effective dose.
Comparative example 2
A pharmaceutical composition for treating cervical cancer comprises an effective amount of apatinib.
Comparative example 3
A pharmaceutical composition for treating cervical cancer comprises an effective amount of licochalcone B and apatinib, wherein the molar ratio of the licochalcone B to the apatinib is 2: 1.
In vitro cell experiments
1. Experimental materials:
HeLa S3 (human cervical cancer cell line)
2. The experimental method comprises the following steps:
cell lines grown in log phase were quantified (about 10 per well)3Individual cells) were added to a 96-well culture plate, and after 24 hours of complete cell adhesion, the pharmaceutical compositions of examples 1-5 and comparative examples 1-3 (0.125. mu.g/ml, 0.25. mu.g/ml, 0.50. mu.g/ml, 1.00. mu.g/ml, 2.00. mu.g/ml, 4.00. mu.g/ml, 8.00. mu.g/ml, 16.00. mu.g/ml, 32.00. mu.g/ml, 64.00. mu.g/ml) were added at different concentrations, with 4 duplicate wells being set for each concentration. The negative control group was added with complete medium. Culturing at 37 deg.C for 48h, adding 5mg/ml MTT solution 10 μ l into each well, culturing for 4h, discarding supernatant, adding 150 μ l DMSO into each well, shaking for dissolving, and rapidly measuring absorbance at 570nm with enzyme-labeling instrumentAnd (4) degree OD value.
3. The calculation method comprises the following steps:
growth Inhibition (GI) × 1- (drug group OD value/negative control group OD value) × 100%. Calculating IC of 48 hours of drug action by SPSS (logit method) according to inhibition rate of each experimental group and negative control group50. The results of the experiment are shown in table 1.
TABLE 1 in vitro IC of pharmaceutical compositions50Measurement of (2)
| Group of | IC50(μg/ml) |
| Example 1 | 6.32±0.37 |
| Example 2 | 8.29±0.52 |
| Example 3 | 8.38±0.59 |
| Example 4 | 7.11±0.68 |
| Example 5 | 7.36±0.62 |
| Comparative example 1 | 17.37±1.77 |
| Comparative example 2 | 48.11±2.78 |
| Comparative example 3 | 8.52±0.60 |
The experimental results in table 1 show that the pharmaceutical composition of the present invention has a strong inhibitory effect on human cervical cancer cell line HeLa S3. Compared with the single use of licochalcone (comparative example 1) or VEGFR inhibitor (comparative example 2), the combined use of the licochalcone and the VEGFR inhibitor (examples 1-5) has more obvious effect of inhibiting the growth of tumor cells and has synergistic inhibition effect on a HeLa S3 cell line. Specifically, when the VEGFR inhibitor in the pharmaceutical composition is apatinib (example 1), its inhibitory effect is superior to that of imatinib (example 2) and lapatinib (example 3), IC50The value can be as low as 6.32. mu.g/ml. In addition, suitable molar ratios between licochalcone and VEGFR inhibitors were also investigated (examples 1,4,5 and comparative example 3), and it was found that when licochalcone B and apatinib were present in a molar ratio of 1:3 when the components are mixed, the growth inhibition effect of the tumor cells is optimal, and the treatment effect of the medicine can be obviously improved.
Inhibition effect of pharmaceutical composition on HeLa S3 (human cervical carcinoma cell) rat transplantation tumor
1. Selection of animals and cell lines:
90 SPF-grade female SD rats (30. + -. 3 g) of 5 weeks old were selected. The cages were housed in 9 cages, 10 per cage. The temperature of the breeding environment is 16-18 deg.C, and the relative humidity is 35-40%. HeLa S3 (human cervical carcinoma cells) was purchased from the cell bank of Chinese academy of sciences.
2. Establishing a model:
suspending and precipitating HeLa S3 cell serum-free culture medium in logarithmic growth phase, counting under microscope, and adjusting cell suspension concentration to (1.5-2) × 108And each/ml, the number of living cells is observed to be more than 90% by staining, 0.2ml of HeLa S3 cell suspension is injected under the skin of the thigh root of a rat in a sterile environment, and a rat model of human cervical carcinoma HeLa S3 cells is established.
3. Grouping and medicine intervention:
successfully modeled rats were randomly divided into 9 groups on day 15, model group + examples 1-5+ comparative examples 1-3, 10 per group. Each administration group is injected into the abdominal cavity, and the model group is injected into the abdominal cavity with the same amount of normal saline for 1 time/day and is continuously administered for 14 days. Wherein the daily dose of each administration group is 50mg/kg, and the daily dose of the VEGFR inhibitor can be converted by a molar ratio between the two.
4. Detection of tumor inhibition effect:
after 14 days, the drug is stopped for 24 hours, the rat is killed by removing the neck, the tumor tissue is completely stripped, the tumor mass condition and the infiltration of peripheral tissues of each group are observed, the ascites and the metastasis of other organs are observed, the tumor mass is measured, and the tumor inhibition rate is calculated. The results of the experiment are shown in table 2.
TABLE 2 inhibitory Effect of the pharmaceutical compositions on HeLa S3 rat transplantable tumors
| Grouping | Mass of tumor before treatment (g) | Tumor mass (g) after treatment | Tumor inhibition Rate (%) |
| Model set | 1.75±0.16 | 1.98±0.18 | - |
| Example 1 | 1.72±0.11 | 0.62±0.15 | 64.0％ |
| Example 2 | 1.74±0.12 | 0.92±0.13 | 47.1％ |
| Example 3 | 1.73±0.17 | 0.87±0.09 | 49.7％ |
| Example 4 | 1.70±0.20 | 0.73±0.16 | 57.1％ |
| Example 5 | 1.77±0.21 | 0.71±0.06 | 59.9％ |
| Comparative example 1 | 1.76±0.19 | 1.08±0.24 | 38.3％ |
| Comparative example 2 | 1.74±0.18 | 1.53±0.22 | 12.1％ |
| Comparative example 3 | 1.71±0.14 | 0.90±0.07 | 47.4％ |
As can be seen from the experimental results in table 2, when licochalcone (comparative example 1) or VEGFR inhibitor (comparative example 2) was used in combination (examples 1 to 5), the effect of resisting cervical cancer was more significant, and the synergistic inhibitory effect was exhibited on HeLa S3 cell line, as compared to when licochalcone alone (comparative example 1) or VEGFR inhibitor alone (comparative example 2). Specifically, when the VEGFR inhibitor in the pharmaceutical composition is apatinib (example 1), its anticancer effect is superior to that of imatinib (example 2) and lapatinib (example 3). In addition, suitable molar ratios between licochalcone and VEGFR inhibitors were also investigated (examples 1,4,5 and comparative example 3), and it was found that when licochalcone B and apatinib were present in a molar ratio of 1:3, the inhibition effect is optimal when the components are mixed, and the treatment effect of the medicine can be obviously improved.
The above description is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, several modifications or equivalents may be made to the technical solution without departing from the principle of the present invention, and these modifications or equivalents should also be regarded as the protection scope of the present invention.
Claims (10)
1. A pharmaceutical composition for treating cervical cancer, which is characterized by comprising an effective amount of licochalcone and a VEGFR inhibitor.
2. The pharmaceutical composition of claim 1, wherein the molar ratio of licochalcone and VEGFR inhibitor is (1-5) to (5-10).
3. The pharmaceutical composition of claim 2, wherein the molar ratio of licochalcone to VEGFR inhibitor is 1: 3.
4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the licochalcone is licochalcone B.
5. The pharmaceutical composition of any of claims 1-3, wherein the VEGFR inhibitor is selected from one or more of apatinib, imatinib, and lapatinib.
6. The pharmaceutical composition of claim 5, wherein the VEGFR inhibitor is selected from apatinib.
7. The pharmaceutical composition of any one of claims 1-3, wherein the cervical cancer is cervical squamous cell carcinoma.
8. A pharmaceutical preparation having an effect of treating cervical cancer, comprising the pharmaceutical composition of any one of claims 1 to 7 and pharmaceutically conventional excipients.
9. The pharmaceutical preparation according to claim 8, wherein the preparation is selected from one or more of tablets, capsules, granules and injections.
10. Use of a pharmaceutical composition according to any one of claims 1 to 7 in the manufacture of a medicament for the treatment of cervical cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010194278.2A CN111265665B (en) | 2020-03-16 | 2020-03-16 | Pharmaceutical composition for treating cervical cancer and pharmaceutical application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010194278.2A CN111265665B (en) | 2020-03-16 | 2020-03-16 | Pharmaceutical composition for treating cervical cancer and pharmaceutical application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111265665A true CN111265665A (en) | 2020-06-12 |
| CN111265665B CN111265665B (en) | 2020-12-18 |
Family
ID=70992439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010194278.2A Expired - Fee Related CN111265665B (en) | 2020-03-16 | 2020-03-16 | Pharmaceutical composition for treating cervical cancer and pharmaceutical application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111265665B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108187055A (en) * | 2018-03-06 | 2018-06-22 | 北京大学 | A kind of anti-cancer composition with synergistic function |
| CN108698999A (en) * | 2015-11-20 | 2018-10-23 | 李镐允 | Quinolone chalcone compound and application thereof |
| CN108939080A (en) * | 2018-10-08 | 2018-12-07 | 黄泳华 | The purposes of composition containing tyrosine kinase inhibitor and resveratrol in the preparation of antitumor drugs |
| CN109893654A (en) * | 2017-12-11 | 2019-06-18 | 江苏恒瑞医药股份有限公司 | The method of VEGFR inhibitor for treating tumour |
| CN110812384A (en) * | 2019-12-20 | 2020-02-21 | 江西中医药大学 | New medical application of effective component and derivative thereof in liquorice |
-
2020
- 2020-03-16 CN CN202010194278.2A patent/CN111265665B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108698999A (en) * | 2015-11-20 | 2018-10-23 | 李镐允 | Quinolone chalcone compound and application thereof |
| CN109893654A (en) * | 2017-12-11 | 2019-06-18 | 江苏恒瑞医药股份有限公司 | The method of VEGFR inhibitor for treating tumour |
| CN108187055A (en) * | 2018-03-06 | 2018-06-22 | 北京大学 | A kind of anti-cancer composition with synergistic function |
| CN108939080A (en) * | 2018-10-08 | 2018-12-07 | 黄泳华 | The purposes of composition containing tyrosine kinase inhibitor and resveratrol in the preparation of antitumor drugs |
| CN110812384A (en) * | 2019-12-20 | 2020-02-21 | 江西中医药大学 | New medical application of effective component and derivative thereof in liquorice |
Non-Patent Citations (1)
| Title |
|---|
| 米热古丽等: "《甘草查尔酮B及其衍生物的制备及抗宫颈癌活性》", 《食品安全质量检测学报》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111265665B (en) | 2020-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20160103148A (en) | Anti-tumoural effects of cannabinoid combinations | |
| CN105769891B (en) | Low polarity rare ginsenoside mixture and application thereof | |
| CN101612400A (en) | 1 application of receptor antagonist in antitumor of angiotensin | |
| TW201406371A (en) | Magnolol for new treatment of bladder cancer and/or inhibition of cancer metastasis and/or improvement of cachexia | |
| CN110123809A (en) | 5- methyl-dihydro benzofuran-application of the imidazole salt compound in pharmacy | |
| CN111265665B (en) | Pharmaceutical composition for treating cervical cancer and pharmaceutical application thereof | |
| CN108295085B (en) | Application of protodioscin in preparation of drug-resistant osteosarcoma drug | |
| CN116726021A (en) | Combined medicine of DRP1 inhibitor and iron death inducer and anti-tumor application thereof | |
| CN111494385B (en) | Medicine for treating ovarian cancer and preparation method and application thereof | |
| CN112043698B (en) | Application of small molecule drugs in preparation of drugs for inhibiting sarcomas | |
| CN101485665A (en) | Novel medical use of cucurbitacin | |
| CN104800204A (en) | Morusin anti-tumor application | |
| TWI469784B (en) | Therapeutic compositoin for treating cancers | |
| CN112603920A (en) | Application of traditional Chinese medicine toosendanin in preparation of products for preventing and treating glioma of nervous system | |
| CN107412736B (en) | Anti-tumor combined medicine and application thereof in preparing anti-cancer medicine | |
| CN102319260A (en) | The application of cisplatin combined itraconazole isomer in preparation treatment lung-cancer medicament | |
| CN111821319A (en) | Application of periplaneta americana extract CII-3 in toxicity-reducing and synergistic antitumor drug cisplatin | |
| CN113440534A (en) | Application of verbascoside in preparation of medicines | |
| CN101347425B (en) | Uses of ampelopsin and total flavone valid target rich in ampelopsin in preparing medicament for preventing and treating prostate gland cancer | |
| CN101120938A (en) | Application of chlorogenic acid in preparing medicine for treating small cell lung cancer | |
| CN105517558A (en) | Filipendula vulgaris extract and uses thereof | |
| WO2019037671A1 (en) | Medicine for combined use in cancer treatment | |
| CN114668757B (en) | Application of pseudolaric acid B in preparing medicine for preventing and/or treating malignant tumor | |
| CN115487179B (en) | Anti-tumor combined medicine and application thereof | |
| CN112915086B (en) | Pharmaceutical composition containing Akt targeted kinase inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20201218 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |